title: Sumatriptan/Naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes.
abstract: OBJECTIVE
  To describe the pain relief, satisfaction, and health-related quality of life results of moderate or severe migraines treated with a sumatriptan/naproxen sodium combination tablet.
  
  
  METHODS
  Sumatriptan and naproxen sodium as a single-dose formulation tablet was used to treat moderate to severe migraines over a 12-month period in a phase 3, open-label, multicenter study (n = 565) in patients with at least 6 months' history of migraine headaches.
  
  
  RESULTS
  Seventy percent of all attacks were treated with 1 dose of sumatriptan/naproxen sodium. Overall subjects treated 24,485 attacks; of these, 81% attacks achieved pain relief and 60% pain-free by 2 hours. At 3 months, the percentage of patients satisfied or very satisfied increased from baseline on all 8 Patient Perception of Migraine Questionnaire (PPMQ) items and remained high throughout the study. Mean Migraine-Specific Quality of Life Questionnaire (MSQ) domain scores also increased by 13-15 points from baseline during this time and remained high.
  
  
  CONCLUSIONS
  Sumatriptan/naproxen sodium provides consistent relief of migraine attacks over 12 months, resulting in improved patient satisfaction and migraine specific quality of life.
authors.affiliation: Mercy Health Research and Ryan Headache Center, St. Louis, MO 63141, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Smith
authors.forename: Harvey
authors.initials: H
authors.lastname: Blumenthal
authors.forename: Merle
authors.initials: M
authors.lastname: Diamond
authors.forename: Alexander
authors.initials: A
authors.lastname: Mauskop
authors.forename: Michael
authors.initials: M
authors.lastname: Ames
authors.forename: Susan
authors.initials: S
authors.lastname: McDonald
authors.forename: Shelley
authors.initials: S
authors.lastname: Lener
authors.forename: Steven
authors.initials: S
authors.lastname: Burch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000523:psychology*; D010147:Pain Measurement; D017060:Patient Satisfaction; D011788:Quality of Life; D018170:Sumatriptan / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D018170:Sumatriptan